Kezdőlap・Részvénylista・AnaptysBio Inc

AnaptysBio Inc

Nyitva

SzektorEgészségügy

55.79 -2.7

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

55.63

Maximum

57.81

Fő mutatók
By Trading Economics
Bevétel	-102M -53M
Értékesítés	-83M 26M
Egy részvényre jutó nyereség	-1.34
Profit margin	-206.934
Munkavállalók	104
EBITDA	-99M -31M

Ajánlások
By TipRanks
Ajánlások	Erős vétel
12 hónapos előrejelzés	+47.93% upside

Osztalékok
By Acuity
Következő eredményjelentés	2026. szept. 1.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	-267M 1.7B
Előző nyitás	58.49
Előző zárás	55.79

Hangulat hírek alapján

By Acuity

41%

59%

124 / 340 Rangsor szerint Healthcare

AnaptysBio Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 27. 23:01 UTC

AnaptysBio Inc shares are lower in after-market trading, continuing a decline over the past three sessions with no specific news identified.

2026. aug. 26. 23:21 UTC

AnaptysBio Inc shares are lower in after-market trading, reflecting increased volatility despite being above its 20-day moving average and near a one-month range high.

2026. aug. 25. 19:46 UTC

AnaptysBio Inc shares are lower during Tuesday's session, pulling back from earlier highs amid a lack of specific news to explain the decline.

2026. aug. 24. 23:01 UTC

AnaptysBio Inc shares are lower in after-market trading, reaching their lowest point of the day amid broader market concerns over geopolitical tensions and inflation.

2026. aug. 21. 19:46 UTC

AnaptysBio Inc shares are higher today, reflecting positive market momentum. The stock has pulled back from an earlier session high but remains up since Thursday.

2026. aug. 20. 20:06 UTC

AnaptysBio Inc shares are lower today, continuing a decline since Wednesday amid rising U.S. Treasury yields and crude oil prices. No specific news was identified.

2026. aug. 19. 19:26 UTC

AnaptysBio Inc shares are higher during Wednesday's session, trading above Tuesday's close and near the upper end of their one-month range. No specific news was identified.

2026. aug. 17. 19:56 UTC

News

AnaptysBio Inc shares are higher following significant institutional buying, including a 283.2% increase by Bank of America Corp in Q1 2026.

2026. aug. 14. 21:01 UTC

AnaptysBio Inc shares are lower in after-market trading, reflecting broader market weakness amid disappointing U.S. retail sales data and concerns over consumer demand.

2026. aug. 12. 19:26 UTC

AnaptysBio Inc shares are lower today, continuing a decline since Tuesday's close, despite earlier intraday gains. No specific news was identified for the movement.

2026. aug. 11. 19:36 UTC

AnaptysBio Inc shares are higher today, reflecting an upward movement of over 2% since Monday's close amid notable intraday volatility.

2026. aug. 10. 19:46 UTC

AnaptysBio Inc shares are lower today, continuing a decline since Friday. Broader market sentiment is influenced by recent labor market data.

2026. aug. 7. 19:26 UTC

AnaptysBio Inc. shares are trading higher today, continuing a trend since Thursday's close, despite notable volatility during the session.

2026. aug. 5. 19:36 UTC

AnaptysBio Inc. shares are lower in Wednesday's session, having declined from earlier highs amid routine market fluctuations and trading near the lower end of its recent range.

2026. aug. 3. 20:06 UTC

AnaptysBio Inc shares are higher today, recovering from earlier losses amid a broader market rally in the S&P 500 and Nasdaq 100 indices.

2026. júl. 31. 20:06 UTC

AnaptysBio Inc shares are lower, reflecting broader market weakness amid rising Treasury yields and crude oil prices, with no specific company news identified.

2026. júl. 30. 23:36 UTC

AnaptysBio Inc. shares declined after-market, reflecting ongoing weakness amid broader market volatility and the Federal Reserve's interest rate decisions.

2026. júl. 29. 19:56 UTC

Macro Event

AnaptysBio Inc shares are higher, recovering from an earlier dip, amid market volatility following the Federal Reserve's decision to maintain interest rates steady.

2026. júl. 28. 23:16 UTC

AnaptysBio Inc shares are higher in after-market trading, recovering from earlier lows. No specific news was identified to explain the movement.

2026. júl. 24. 19:16 UTC

AnaptysBio Inc shares are lower today, reflecting a decline since Thursday. Broader market sentiment is affected by recent volatility in oil prices.

2026. júl. 23. 09:16 UTC

AnaptysBio Inc is trading lower in pre-market hours amid broader market pressures from disappointing earnings reports and rising geopolitical tensions.

2026. júl. 22. 22:16 UTC

AnaptysBio Inc shares are higher in after-market hours, trading above Wednesday's close amid broader market concerns over rising crude oil prices and U.S.-Iran tensions.

2026. júl. 21. 20:12 UTC

AnaptysBio Inc. shares are lower in after-market trading, continuing a downward trend and positioning the stock below its 20-day moving average.

2026. júl. 20. 23:01 UTC

AnaptysBio Inc. shares are higher in after-market trading, reflecting routine activity. The stock remains below its 20-day moving average.

Társak összehasonlítása

Árváltozás

AnaptysBio Inc Előrejelzés

Célár

By TipRanks

47.93% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 84.75 USD 47.93%

Magas 95 USD

Alacsony 75 USD

5 Wall Street elemző 12 hónapos célárain alapulva a(z)AnaptysBio Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

5 ratings

Vétel

Tartás

Eladás

5 Wall Street elemző célárain alapulva a(z)AnaptysBio Inc termékhez az elmúlt 3 hónapban.

Hangulat

By Acuity

124 / 340 Rangsor szerint Egészségügy

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.